Have a question?
Please get in touch with our team in case of any queries
HPV TESTING MARKET SIZE TO CROSS USD 1.1 BILLION BY 2025, GROWING AT A CAGR OF 12% DURING THE FORECAST PERIOD
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
HPV TESTING MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (REVENUE) | USD 1.1 BILLION (2025) |
| CAGR | 12% (2020 - 2025) |
| Base Year | 2019 |
| Forecast Year | 2020-2025 |
| Market Segments | Products (Consumables, Instruments), Applications (Cervical Cancers, Vaginal Cancers, Others), End-user (Standard Reference Laboratories, Hospitals, Physicians’ Office and Clinics) |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, Germany, France, UK, Spain, Italy, Japan, China, India, Australia, South Korea, Brazil, Mexico, Argentina, Turkey, Saudi Arabia, and South Africa |
INDUSTRY INSIGHTS
The HPV testing market size to cross USD 1.1 billion by 2025, growing at a CAGR of 12% during the forecast period. The increased procurement of the latest generation HPV testing analyzers and test kits, coupled with the high prevalence of HPV infections and cancers, especially cervical and vaginal, influences the growth of the global HPV testing market. Traditionally, cervical cancer screening was based on cervical cytology or pap test. However, in recent years, several countries and global health bodies have recommended the inclusion of HPV tests for cervical and pre-cancer screening programs, which is likely to boost the market.
The demand for new innovative testing consumables and instruments using advanced techniques such as the HPV mRNA test, which promotes accurate and sensitive diagnostic outcomes, is driving the market growth. Further, with the availability of positive clinical evidence, demonstrating the superiority of the latest generation advanced testing devices, end-users will become increasingly aware of clinical benefits and rapidly adopt these tests as an essential screening tool for cervical cancer screening. Therefore, the improvement in patient management, favorable government initiatives for primary screening, and the rising awareness of advanced testing in developed and developing economies are increasing the adoption globally.
SNIPPETS
- Approximately 570,000 cases of human papillomavirus cervical cancer cases are diagnosed annually across the globe. Cervical cancer in the US is the third most common disease among women, with over 14,065 new cases reported every year.
- About 85% of diagnosed cervical cancers and related deaths occur among women living in lower-middle-income countries. China and India have the highest numbers of people with cervical cancers.
- The growing awareness related to HPV testing for cervical cancer screening is contributing to the uptake of instruments and consumables.
- Vendors need to focus on the development of mRNA HPV testing for high sensitivity and accuracy.
HPV TESTING MARKET SEGMENTATION
This research report includes detailed segmentation by
- Products
- Applications
- End-user
- Geography
INSIGHTS BY PRODUCTS
The consumables segment is growing due to the high adoption of advanced testing kits, reagents, and other related consumables to detect and screen cervical cancers globally. The segment is also growing at a fast rate due to the recurring purchase by end-users to perform HPV tests. These screening tests are likely to gain wide acceptance in emerging economies. The growth is due to favorable government initiatives and the rise in consumer spending power. Therefore, market players are focusing on significant product launches in a low resource setting of emerging countries, thereby boosting the segment growth.
The instruments segment is growing at a slow pace as the procurement of analyzers is capital intensive and the purchasing decision depends on financial resources and budget allocations. However, the increasing availability of automated and compact analyzers/instruments has significantly improved the efficiency and quality of end-user operations. Automation and integration of several diagnostic platforms have led to the introduction of innovative diagnostic analyzers. This is driving the growth of the segment during the forecast period.
INSIGHTS BY APPLICATION
The cervical cancer application segment accounted for 80% market share of the global HPV testing market. The cervical application segment is growing on account of the rise in cervical cancer incidences. The launch of screening products in low resource countries is expected to drive the cervical application segment during the upcoming years. In the US region, HPV self-sampling is emerging as a potential cancer screening strategy. This is likely to contribute to market growth.
The application of HPV testing for vaginal cancer offers powerful negative predictive values. Therefore, the detection of infection with a high-risk HPV, which produce visible signs, is a powerful tool for vaginal cancer screening. The benefit of HPV testing, rising vaginal cancer, and innovative testing devices are driving the growth of the vaginal application segment.
INSIGHTS BY END-USERS
In 2019, the standard reference laboratories segment accounted for 40% of the global HPV testing market. The standard reference laboratories help in improving overall diagnostic outcomes.
Healthcare professionals in hospitals use HPV testing as a screening procedure for cervical and other related cancers. The hospital segment is likely to grow at the fastest CAGR during the forecast period. A majority of patients with high-risk symptoms prefer visiting hospitals for diagnosis due to advanced infrastructure facilities.
The physicians’ office and clinic segment is expected to grow mainly on account of the growing prevalence of cervical cancers worldwide. The market is growing at a healthy rate with 12% CAGR during the forecast period. Another factor responsible for the rise of this segment is the availability of super-specialty expertise in these clinics.
INSIGHTS BY GEOGRAPHY
North America is growing at a healthy rate and this trend is likely to continue during the forecast period. The growth is due to the growing preference for HPV tests to detect and screen cervical cancers and other related infections. The United States region is the major revenue contributor to the North America HPV testing market. The region accounted for a share of 95% in 2019.
The HPV testing market share in Europe is the second-largest and accounted for a 24% share in 2019. Germany, France, the UK, Spain, and Italy are the leading contributors to the Europe region.
The APAC region has the highest population with a high risk of developing cervical cancers and other associated infections. Japan, China, Australia, South Korea, and India are the major revenue contributors from the region. Japan is the major revenue contributor to the HPV testing market in APAC. The growth is due to advancements in healthcare infrastructure, the rise in healthcare expenditure, and favorable public and private initiatives for an increase in healthcare access.
INSIGHTS BY VENDORS
The global HPV testing market share is highly competitive and characterized by the presence of several global, regional, and local players. F. Hoffmann-La Roche, QIAGEN, Hologic, and Abbott Laboratories are the dominant players. Their testing instruments and consumables are widely used by end-users globally. These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on innovation and research activities. Over the years, these players have been dominating the market as they have introduced safe and efficient products in the market.
The global HPV testing market research report includes in-depth coverage of the industry analysis with revenue, growth trends, and forecast insights for the following segments:
Market Segmentation by Products
- Consumables
- Instruments
By Applications
- Cervical Cancers
- Vaginal Cancers
- Others
By End-user
- Standard Reference Laboratories
- Hospitals
- Physicians’ Office and Clinics
By Geography
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- APAC
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
SNAPSHOT
The global HPV testing market is expected to grow at a CAGR of over 12% during the period 2019–2025.
The following factors are likely to contribute to the growth of the HPV testing market during the forecast period:
- Increasing Prevalence of HPV Infections
- Emergence of Point-of-care Diagnostics/Rapid HPV Tests
- Rise of mRNA Test for Cervical Cancer Screening
- Increasing Demand for HPV Co-testing
Base Year: 2019
Forecast Year: 2020–2025
The study considers the present scenario of the HPV testing market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent companies operating in the market.
Key Vendors
- Hoffmann-La Roche
- Business Overview
- Major Product Offerings
- Key Strengths
- Key Strategies
- Key Opportunities
- QIAGEN
- Hologic
- Abbott
Other Vendors
- Arbor Vita
- Business Overview
- Product Offerings
- BD
- Cepheid
- DAAN Gene
- DiaCarta
- Fujirebio
- Greiner Bio One International
- Hybribio
- IncellDx
- Norgen Biotek
- PreTect
- Seegene
- Siemens Healthineers
- Takara Bio
- Xiamen Zeesan Biotech
- ZYTOVISION
Market Segmentation by Products
- Consumables
- Instruments
Market Segmentation by Applications
- Cervical Cancers
- Vaginal Cancers
- Others
Market Segmentation by End-user
- Standard Reference Laboratories
- Hospitals
- Physicians’ Office and Clinics
Market Segmentation by Geography
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- APAC
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
Frequently Asked Questions
What is the HPV testing market size and growth forecast?
What are the factors impacting the growth of the market?
Who are the key players in the HPV testing market?
Which segment is contributing to the HPV testing market growth?
List of Exhibits
Exhibit 1 Segmentation of Global HPV Testing Market
Exhibit 2 Market Size Calculation Approach 2019
Exhibit 3 Symptoms of HPV
Exhibit 4 Different Types of Human Papillomavirus Based on Risk
Exhibit 5 Symptoms of Advanced Cervical Cancer
Exhibit 6 Major Market Dynamics in Global HPV Testing Market
Exhibit 7 Global HPV Testing Market by Geography 2019 (%)
Exhibit 8 Global HPV Testing Market by Product 2019 (%)
Exhibit 9 Impact of Increasing Prevalence of Human Papillomavirus Infections
Exhibit 10 Cervical Cancer Incidence & Mortality Rate
Exhibit 11 Worldwide Prevalence of Human Papillomavirus Types
Exhibit 12 Impact of Growing Awareness & Favorable Guidelines Endorsing Human Papillomavirus Testing
Exhibit 13 Updated Screening Guidelines for Cervical Cancer by US Preventive Services Task Force for Women in the Age Range of 30-65 Years in August 2018
Exhibit 14 Impact of High Demand for Nucleic Acid Amplification Tests
Exhibit 15 Scenarios where HPV DNA Test is Recommended
Exhibit 16 Impact of Availability of Alternative Diagnostic Methods for Human Papillomavirus
Exhibit 17 Key Advantages of Pap Tests
Exhibit 18 Key Advantages of VIA
Exhibit 19 Impact of Increasing Focus on Preventive Measures for Human Papillomavirus Infections
Exhibit 20 Impact of HPV Vaccination on HPV Infections in Various Age Groups
Exhibit 21 Impact of Lower than Expected Market Penetration of Human Papillomavirus Tests
Exhibit 22 Key Factors Hindering the Expected Market Penetration of HPV Testing in Developing Countries
Exhibit 23 Impact of Emergence of Point-of-care/Rapid Human Papillomavirus Tests
Exhibit 24 Impact of High Growth Potential for Human Papillomavirus Tests in Low Resource Settings of LMICs
Exhibit 25 Top 10 Countries with Highest Cervical Cancer Rate in 2018
Exhibit 26 Comparison of Cervical Cancer Mortality Rates in Less Developed and Developed Countries by Age Groups
Exhibit 27 Impact of Emergence of mRNA Test for Cervical Cancer Screening
Exhibit 28 The Most Important Advantages of mRNA Human Papillomavirus Test
Exhibit 29 Impact of Increasing Demand for HPV Co-testing
Exhibit 30 Use of Human Papillomavirus DNA Testing as an Adjunct to Cytology for Cervical Cancer Screening in Women 30 Years and Older
Exhibit 31 Global HPV Testing Market 2019−2025 ($ million)
Exhibit 32 Global HPV Testing Market by Geography
Exhibit 33 Global HPV Testing Market by Product
Exhibit 34 Global HPV Testing Market by Application
Exhibit 35 Global HPV Testing Market by End-users
Exhibit 36 Five Force Analysis 2019
Exhibit 37 Incremental Growth by Product 2019-2025
Exhibit 38 Global Market by Product
Exhibit 39 Global Market Lifecycle by Product
Exhibit 40 Global Market by Product: Incremental Growth
Exhibit 41 Global Market by Product: Absolute Growth
Exhibit 42 Global Market by Product 2019−2025 ($ million)
Exhibit 43 Global Market by Product 2019−2025 (%)
Exhibit 44 Global Market by Consumables: Absolute & Incremental Growth
Exhibit 45 High-risk HPV-induced Cancers
Exhibit 46 Human Papillomavirus Testing Equipment Market 2019−2025 ($ million)
Exhibit 47 Global HPV Testing Market by Instruments: Absolute & Incremental Growth
Exhibit 48 Human Papillomavirus Testing Instruments Market 2019−2025 ($ million)
Exhibit 49 Incremental Growth by Application 2019-2025
Exhibit 50 Global Market by Application
Exhibit 51 Global Market Lifecycle by Application
Exhibit 52 Global Market by Application: Incremental Growth
Exhibit 53 Global Market by Application: Absolute Growth
Exhibit 54 Countries with Highest Cervical Cancer Rate in 2018
Exhibit 55 Potential Uses of HPV Testing
Exhibit 56 Human Papillomavirus Testing Market by Cervical Cancer: Absolute & Incremental Growth
Exhibit 57 Global Market by Cervical Cancer 2019−2025 ($ million)
Exhibit 58 Global Vaginal Cancer Incidence 2018
Exhibit 59 Global Market by Vaginal Cancer: Absolute & Incremental Growth
Exhibit 60 HPV Genotype Distribution in Vaginal Cancer Cases (%)
Exhibit 61 Global Market by Vaginal Cancer 2019−2025 ($ million)
Exhibit 62 Global Market by Other Cancers: Absolute & Incremental Growth
Exhibit 63 Global Oropharyngeal Cancer Incidence 2018
Exhibit 64 Global Vulvar Cancer Incidence 2018
Exhibit 65 Global Anal Cancer Incidence 2018
Exhibit 66 Global Penile Cancer Incidence 2018
Exhibit 67 Global HPV Testing Market by Others 2019−2025 ($ million)
Exhibit 68 Incremental Growth by End-users 2019-2025
Exhibit 69 Global Market by End-users
Exhibit 70 Global Market Lifecycle by End-users
Exhibit 71 Global Market by End-users: Absolute Growth
Exhibit 72 Global Market by End-users: Incremental Growth
Exhibit 73 Global Market by Standard Reference Laboratories: Absolute & Incremental Growth
Exhibit 74 Key Offerings by WHO LabNet for Standard Reference Laboratories
Exhibit 75 Global Market by Standard Reference Laboratories 2019−2025 ($ million)
Exhibit 76 Global Market by Hospitals: Absolute & Incremental Growth
Exhibit 77 Global Market by Hospitals 2019−2025 ($ million)
Exhibit 78 Global Market by Physicians’ Offices and Clinics: Absolute & Incremental Growth
Exhibit 79 Global Market by Physicians’ Offices and Clinics 2019−2025 ($ million)
Exhibit 80 Incremental Growth by Geography 2019-2025
Exhibit 81 Global Market by Geography
Exhibit 82 Global Market Lifecycle by Region
Exhibit 83 Global Market by Geography 2019
Exhibit 84 Global Market by Geography: Absolute Growth
Exhibit 85 Global Market by Geography: Incremental Growth
Exhibit 86 Human Papillomavirus Testing Market in North America
Exhibit 87 North America HPV Testing Market: Absolute & Incremental Growth
Exhibit 88 Market in North America 2019−2025 ($ million)
Exhibit 89 North America: Market by Product 2019 & 2025 (%)
Exhibit 90 North America: Market by Product 2019−2025 ($ million)
Exhibit 91 North America: Market by Product 2019−2025 (%)
Exhibit 92 Incremental Growth in North America 2019−2025
Exhibit 93 Market in US 2019−2025 ($ million)
Exhibit 94 Market in Canada 2019−2025 ($ million)
Exhibit 95 Europe HPV Testing Market 2019
Exhibit 96 Europe Market: Absolute & Incremental Growth
Exhibit 97 Market in Europe 2019–2025 ($ million)
Exhibit 98 Incremental Growth in Europe 2019-2025
Exhibit 99 Europe: Market by Product 2019−2025 ($ million)
Exhibit 100 Europe: Market by Product 2019−2025 (%)
Exhibit 101 Market in UK 2019−2025 ($ million)
Exhibit 102 The YPA Program Mainly Includes
Exhibit 103 Market in France 2019–2025 ($ million)
Exhibit 104 Market in Germany 2019–2025 ($ million)
Exhibit 105 Market in Italy 2019–2025 ($ million)
Exhibit 106 Market in Spain 2019–2025 ($ million)
Exhibit 107 APAC HPV Testing Market 2019
Exhibit 108 APAC Market: Absolute & Incremental Growth
Exhibit 109 Market in APAC 2019–2025 ($ million)
Exhibit 110 APAC: Market by Product 2019−2025 ($ million)
Exhibit 111 APAC: Market by Product 2019−2025 (%)
Exhibit 112 Incremental Growth in APAC 2019-2025
Exhibit 113 Market in Japan 2019–2025 ($ million)
Exhibit 114 Market in China 2019–2025 ($ million)
Exhibit 115 Market in Australia 2019–2025 ($ million)
Exhibit 116 Market in South Korea 2019–2025 ($ million)
Exhibit 117 Market in India 2019–2025 ($ million)
Exhibit 118 Latin America HPV Testing Market 2019
Exhibit 119 Latin America Market: Absolute & Incremental Growth
Exhibit 120 Market in Latin America 2019–2025 ($ million)
Exhibit 121 Latin America: Market by Product 2019−2025 ($ million)
Exhibit 122 Latin America: Market by Product 2019−2025 (%)
Exhibit 123 Incremental Growth in Latin America 2019-2025
Exhibit 124 Market in Brazil 2019–2025 ($ million)
Exhibit 125 Market in Mexico 2019–2025 ($ million)
Exhibit 126 Market in Mexico 2019–2025 ($ million)
Exhibit 127 MEA HPV Testing Market 2019
Exhibit 128 MEA Market: Absolute & Incremental Growth
Exhibit 129 Middle East and North Africa Cervical Cancer Deaths
Exhibit 130 Market in MEA 2019–2025 ($ million)
Exhibit 131 MEA: Market by Product 2019−2025 ($ million)
Exhibit 132 MEA: Market by Product 2019−2025 (%)
Exhibit 133 Incremental Growth in MEA 2019-2025
Exhibit 134 Market in Turkey 2019–2025 ($ million)
Exhibit 135 Market in South Africa 2019–2025 ($ million)
Exhibit 136 Market in Saudi Arabia 2019–2025 ($ million)
Exhibit 137 Global HPV Testing Market Share: Vendors Share 2019
Exhibit 138 F. Hoffmann-La Roche: Revenue by Business Segments in 2017−2018 ($ billion)
Exhibit 139 F. Hoffmann-La Roche: R&D Expenditure in 2016−2018 ($ billion)
Exhibit 140 F. Hoffmann-La Roche: Revenue by Geography ($ billion)
Exhibit 141 QIAGEN: Revenue by Business Segments in 2017−2018 ($ million)
Exhibit 142 QIAGEN: R&D Expenditure in 2016−2018 ($ million)
Exhibit 143 QIAGEN: Revenue by Geography in 2018 ($ million)
Exhibit 144 Hologic: Revenue by Segments 2018−2019 ($ million)
Exhibit 145 Hologic: R&D Expenditure 2017−2019 ($ million)
Exhibit 146 Hologic: Revenue by Geography 2019 ($ million)
Exhibit 147 Abbott: Revenue by Segments 2017−2018 ($ million)
Exhibit 148 Abbott: R&D Expenditure 2016−2018 ($ million)
Exhibit 149 Abbott: Revenue by Geography ($ million)
List of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2014−2019
Table 3 High-risk HPV-induced Cancers
Table 4 Major Vendors Offering HPV Testing Solutions
Table 5 Market Penetration of Human Papillomavirus Test by Regions
Table 6 Commercially Available POC HPV Products
Table 7 Absolute Growth of Human Papillomavirus Testing in Developed and Emerging Economies (%)
Table 8 Commercially Available mRNA Test
Table 9 List of Key HPV Testing Instruments from Market Players
Table 10 Key HPV Diagnostic Analyzers Available in the Market
Table 11 Significant Players Offering Human Papillomavirus Testing Products for the Detection of Cervical Cancer
Table 12 Classification of Human Papillomavirus Associated Penile Carcinomas, Relative Frequency and Mean Cancer-Specific Mortality by WHO
Table 13 Healthcare Expenditure as Percent of GDP in Major Latin American Countries
Table 14 Global HPV Testing Market: Top Vendors Ranking
Table 15 F. Hoffmann-La Roche: Key Product Offerings
Table 16 QIAGEN: Key Product Offerings
Table 17 Hologic: Key Product Offerings
Table 18 Abbott: Key Product Offerings
Table 19 Arbor Vita: Key Product Offerings
Table 20 BD: Key Product Offerings
Table 21 Cepheid: Key Product Offerings
Table 22 DAAN Gene: Key Product Offerings
Table 23 DiaCarta: Key Product Offerings
Table 24 Fujirebio: Key Product Offerings
Table 25 Greiner Bio-One International: Key Product Offerings
Table 26 Hybribio: Key Product Offerings
Table 27 IncellDx: Key Product Offerings
Table 28 Norgen Biotek: Key Product Offerings
Table 29 PreTect: Key Product Offerings
Table 30 Seegene: Key Product Offerings
Table 31 Siemens Healthineers: Key Product Offerings
Table 32 Takara Bio: Key Product Offerings
Table 33 Xiamen Zeesan Biotech: Key Product Offerings
Table 34 ZYTOVISION: Key Product Offerings
Table 35 Global Human Papillomavirus Testing Market by Product ($ million)
Table 36 Market by Product (%)
Table 37 Market by Application ($ million)
Table 38 Market by Application (%)
Table 39 Market by End-users ($ million)
Table 40 Market by End-users (%)
Table 41 Market by Geography ($ million)
Table 42 Market by Geography (%)
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of the study
4.4 Market Segments
4.4.1 Market Segmentation by Product
4.4.2 Market Segmentation by Application
4.4.3 Market Segmentation by End-users
4.4.4 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 HPV Infections: An Overview
7.1.1 Background
7.1.2 Types of Human Papillomavirus
7.1.3 Cervical Cancer
7.1.4 Human Papillomavirus Tests
7.1.5 HPV Testing: Market Snapshot
8 Market Dynamics
8.1 Market Growth Enablers
8.1.1 Increasing Prevalence of Human Papillomavirus Infections
8.1.2 Growing Awareness & Favorable Guidelines Endorsing HPV Testing
8.1.3 High Demand for Nucleic Acid Amplification Tests
8.2 Market Growth Restraints
8.2.1 Availability of Alternative Diagnostic Methods for HPV
8.2.2 Increasing Focus on Preventive Measures for Human Papillomavirus Infections
8.2.3 Lower than Expected Market Penetration of HPV Tests
8.3 Market Opportunities and Trends
8.3.1 Emergence of Point-of-care/Rapid Human Papillomavirus Tests
8.3.2 High Growth Potential for HPV Tests in Low Resource Settings of LMICs
8.3.3 Emergence of mRNA Test for Cervical Cancer Screening
8.3.4 Increasing Demand for Human Papillomavirus Co-testing
9 Global HPV Testing Market
9.1 Market Overview
9.2 Market Size & Forecast
9.2.1 By Geography
9.2.2 By Product
9.2.3 By Application
9.2.4 By End-users
9.3 Five Forces Analysis
9.3.1 Threat of New Entrants
9.3.2 Bargaining Power of Suppliers
9.3.3 Bargaining Power of Buyers
9.3.4 Threat of Substitutes
9.3.5 Competitive Rivalry
10 HPV Testing Market by Product
10.1 Market Snapshot & Growth Engine
10.2 Market Overview
10.3 Consumables
10.3.1 Market Overview
10.3.2 Market Size & Forecast
10.4 Instruments
10.4.1 Market Overview
10.4.2 Market Size & Forecast
11 HPV Testing Market by Application
11.1 Market Snapshot & Growth Engine
11.2 Market Overview
11.3 Cervical Cancer
11.3.1 Market Overview
11.3.2 Market Size & Forecast
11.4 Vaginal Cancer
11.4.1 Market Overview
11.4.2 Market Size & Forecast
11.5 Others
11.5.1 Market Overview
11.5.2 Market Size & Forecast
12 HPV Testing Market by End-Users
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Standard Reference Laboratories
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Hospitals
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.5 Physicians’ Offices and Clinics
12.5.1 Market Overview
12.5.2 Market Size & Forecast
13 HPV Testing Market by Geography
13.1 Market Snapshot & Growth Engine
13.2 Overview
14 North America
14.1 Market Overview
14.2 Market Size & Forecast
14.3 HPV Testing Market Segmentation by Product
14.4 Key Countries
14.4.1 US: Market Size & Forecast
14.4.2 Canada: Market Size & Forecast
15 Europe
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Key Countries
15.4 HPV Testing Market Segmentation by Product
15.4.1 UK: Market Size & Forecast
15.4.2 France: Market Size & Forecast
15.4.3 Germany: Market Size & Forecast
15.4.4 Italy: Market Size & Forecast
15.4.5 Spain: Market Size & Forecast
16 APAC
16.1 Market Overview
16.2 Market Size & Forecast
16.3 HPV Testing Market Segmentation by Product
16.4 Key Countries
16.4.1 Japan: Market Size & Forecast
16.4.2 China: Market Size & Forecast
16.4.3 Australia: Market Size & Forecast
16.4.4 South Korea: Market Size & Forecast
16.4.5 India: Market Size & Forecast
17 Latin America
17.1 Market Overview
17.2 Market Size & Forecast
17.3 HPV Testing Market Segmentation by Product
17.4 Key Countries
17.4.1 Brazil: Market Size & Forecast
17.4.2 Mexico: Market Size & Forecast
17.4.3 Argentina: Market Size & Forecast
18 Middle East & Africa
18.1 Market Overview
18.2 Market Size & Forecast
18.3 HPV Testing Market Segmentation by Product
18.4 Key Countries
18.4.1 Turkey: Market Size & Forecast
18.4.2 South Africa: Market Size & Forecast
18.4.3 Saudi Arabia: Market Size & Forecast
19 Competitive Landscape
19.1 Competition Overview
19.2 Market Share Analysis
19.2.1 F. Hoffmann-La Roche
19.2.2 QIAGEN
19.2.3 Hologic
19.2.4 Abbott
20 Key Vendors
20.1 F. Hoffmann-La Roche
20.1.1 Business Overview
20.1.2 Major Product Offerings
20.1.3 Key Strengths
20.1.4 Key Strategies
20.1.5 Key Opportunities
20.2 QIAGEN
20.2.1 Business Overview
20.2.2 Major Product Offerings
20.2.3 Key Strengths
20.2.4 Key Strategies
20.2.5 Key Opportunities
20.3 Hologic
20.3.1 Business Overview
20.3.2 Major Product Offerings
20.3.3 Key Strengths
20.3.4 Key Strategies
20.3.5 Key Opportunities
20.4 Abbott
20.4.1 Business Overview
20.4.2 Major Product Offerings
20.4.3 Key Strengths
20.4.4 Key Strategies
20.4.5 Key Opportunities
21 Other Prominent Vendors
21.1 Arbor Vita
21.1.1 Business Overview
21.1.2 Major Product Offerings
21.2 BD
21.2.1 Business Overview
21.2.2 Major Product Offerings
21.3 Cepheid
21.3.1 Business Overview
21.3.2 Major Product Offerings
21.4 DAAN Gene
21.4.1 Business Overview
21.4.2 Major Product Offerings
21.5 DiaCarta
21.5.1 Business Overview
21.5.2 Major Product Offerings
21.6 Fujirebio
21.6.1 Business Overview
21.6.2 Major Product Offerings
21.7 Greiner Bio-One International
21.7.1 Business Overview
21.7.2 Major Product Offerings
21.8 Hybribio
21.8.1 Business Overview
21.8.2 Major Product Offerings
21.9 IncellDx
21.9.1 Business Overview
21.9.2 Major Product Offerings
21.10 Norgen Biotek
21.10.1 Business Overview
21.10.2 Major Product Offerings
21.11 PreTect
21.11.1 Business Overview
21.11.2 Major Product Offerings
21.12 Seegene
21.12.1 Business Overview
21.12.2 Major Product Offerings
21.13 Siemens Healthineers
21.13.1 Business Overview
21.13.2 Major Product Offerings
21.14 Takara Bio
21.14.1 Business Overview
21.14.2 Major Product Offerings
21.15 Xiamen Zeesan Biotech
21.15.1 Business Overview
21.15.2 Major Product Offerings
21.16 Zytovision
21.16.1 Business Overview
21.16.2 Major Product Offerings
22 Report Summary
22.1 Key Takeaways
22.2 Strategic Recommendations
22.3 Quantitative Summary
22.3.1 By Product
22.3.2 By Application
22.3.3 By End-users
22.3.4 By Geography
23 Appendix
23.1 Abbreviations
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
What is the HPV testing market size and growth forecast?
What are the factors impacting the growth of the market?
Who are the key players in the HPV testing market?
Which segment is contributing to the HPV testing market growth?
Other RELATED Reports
Drug-Coated Balloons Market - Global Outlook and Forecast 2019-2024
Published : January 2019
Robotic Surgery Devices Market - Global Outlook and Forecast 2019-2024
Published : September 2019
Medical Linear Accelerator Market - Global Outlook and Forecast 2020-2025
Published : December 2019
Cell and Gene Therapy Market - Global Outlook and Forecast 2020-2025
Published : August 2020